



مركز الكويت لمكافحة السرطان
Kuwait Cancer Control Center

ALECTinib (Alecensa®)



* A L C - O O O O - D L - C N - T X *



Ministry of Health

Name:

File #:

Ht (cm):

Nationality:

Civil ID:

Wt (Kg):

Gender/Age:

DOB:

BSA (m²):

Indication(s): Advanced stage ALK positive lung adenocarcinoma:

First-line therapy.

Subsequent-line therapy after failure or intolerance to Crizotinib.

Central line: Available NA

Allergies: NKA Yes, specify; _____

Standard Protocol:

DRUG	DOSE	ADMINISTRATION
ALECTinib	600 mg PO bid	To be given with a meal. If a dose was missed or vomiting occurred, take the next dose at the regularly scheduled time (Don't take an extra dose).
To be given continuously until disease progression or intolerable toxicity.		

Special instructions: Avoid direct sun exposure while on treatment and for 7 days after the last dose. If sun exposure is mandatory, use UVA/B sunscreen and lip balm (at least SPF 50).

Treatment Description:

Cycle	Date	ALECTinib	Physician	Consultant
C# __				
C# __				
C# __				
C# __				
C# __				
C# __				
C# __				
C# __				

Important Notes:

Reported grade 3/4 toxicities: None Hematological Non-Hematological

If yes; Did it indicate hospitalization? Yes No

Did it indicate chemo-delay for ≥ 7 days? Yes No

Did it indicate dose reduction? Yes No

Did it indicate G-CSF support? Yes No